FDA Determines Regulatory Review Period for EDWARDS SAPIEN 3 ULTRA RESILIA PMA Application

Summary

The US Food and Drug Administration (FDA) has determined the regulatory review period for EDWARDS SAPIEN 3 ULTRA RESILIA premarket approval application (PMA) 140031 supplement (S-141), following a patent extension application submitted to the US Patent and Trademark Office (USPTO).